- Home
- INDO vs APLT Comparison
INDO vs APLT Comparison
Compare INDO & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDO
- APLT
- Stock Information
- Founded
- INDO 2018
- APLT 2016
- Country
- INDO Indonesia
- APLT United States
- Employees
- INDO N/A
- APLT N/A
- Industry
- INDO Oil & Gas Production
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- INDO Energy
- APLT Health Care
- Exchange
- INDO Nasdaq
- APLT Nasdaq
- Market Cap
- INDO 40.1M
- APLT 37.5M
- IPO Year
- INDO 2019
- APLT 2019
- Fundamental
- Price
- INDO $2.28
- APLT $0.37
- Analyst Decision
- INDO
- APLT Buy
- Analyst Count
- INDO 0
- APLT 7
- Target Price
- INDO N/A
- APLT $6.10
- AVG Volume (30 Days)
- INDO 188.8K
- APLT 2.3M
- Earning Date
- INDO 04-29-2025
- APLT 04-14-2025
- Dividend Yield
- INDO N/A
- APLT N/A
- EPS Growth
- INDO N/A
- APLT N/A
- EPS
- INDO N/A
- APLT N/A
- Revenue
- INDO $3,127,587.00
- APLT $455,000.00
- Revenue This Year
- INDO N/A
- APLT $3,031.87
- Revenue Next Year
- INDO N/A
- APLT $312.01
- P/E Ratio
- INDO N/A
- APLT N/A
- Revenue Growth
- INDO N/A
- APLT N/A
- 52 Week Low
- INDO $2.06
- APLT $0.30
- 52 Week High
- INDO $5.88
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- INDO 43.27
- APLT 42.55
- Support Level
- INDO $2.21
- APLT $0.31
- Resistance Level
- INDO $2.49
- APLT $0.38
- Average True Range (ATR)
- INDO 0.16
- APLT 0.05
- MACD
- INDO -0.00
- APLT 0.00
- Stochastic Oscillator
- INDO 35.08
- APLT 48.39
About INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.